Please use this identifier to cite or link to this item:
Title: Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease
Authors: Schüller, A. 
Yin, Z.
Brian Chia, C.S.
Doan, D.N.P.
Kim, H.-K.
Shang, L.
Loh, T.P.
Hill, J.
Vasudevan, S.G. 
Keywords: Dengue virus
NS2B-NS3 protease
Peptide inhibitor
West nile virus
Issue Date: Oct-2011
Citation: Schüller, A., Yin, Z., Brian Chia, C.S., Doan, D.N.P., Kim, H.-K., Shang, L., Loh, T.P., Hill, J., Vasudevan, S.G. (2011-10). Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Antiviral Research 92 (1) : 96-101. ScholarBank@NUS Repository.
Abstract: A series of tripeptide aldehyde inhibitors were synthesized and their inhibitory effect against dengue virus type 2 (DENV2) and West Nile virus (WNV) NS3 protease was evaluated side by side with the aim to discover potent flaviviral protease inhibitors and to examine differences in specificity of the two proteases. The synthesized inhibitors feature a varied N-terminal cap group and side chain modifications of a P 2-lysine residue. In general a much stronger inhibitory effect of the tripeptide inhibitors was observed toward WNV protease. The inhibitory concentrations against DENV2 protease were in the micromolar range while they were submicromolar against WNV. The data suggest that a P 2-arginine shifts the specificity toward DENV2 protease while WNV protease favors a lysine in the P 2 position. Peptides with an extended P 2-lysine failed to inhibit DENV2 protease suggesting a size-constrained S 2 pocket. Our results generally encourage the investigation of di- and tripeptide aldehydes as inhibitors of DENV and WNV protease. © 2011 Elsevier B.V.
Source Title: Antiviral Research
ISSN: 01663542
DOI: 10.1016/j.antiviral.2011.07.002
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Oct 3, 2022


checked on Oct 3, 2022

Page view(s)

checked on Oct 6, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.